Bibliothèque

Importance of optimizing duration of adjuvant immune checkpoint inhibitor therapy to treat postoperative hepatocellular carcinoma after conversion therapy: a case report.

Patients with hepatocellular carcinoma at high risk of recurrence after hepatic resection or local ablation often undergo adjuvant immunotherapy with immune checkpoint inhibitors for 1 year in randomi…

Thérapies de Conversion

Li, J. R., Yang, D. L., Wang, J. M., Tian, W., Wei, W., Luo, C. P., Qi, L. N., Ma, L., & Zhong, J. H. (2023). Importance of optimizing duration of adjuvant immune checkpoint inhibitor therapy to treat postoperative hepatocellular carcinoma after conversion therapy: a case report.. J Surg Case Rep, 2023(11), rjad610. https://doi.org/10.1093/jscr/rjad610

01/11/2023 Lire →

Deep radiomics-based fusion model for prediction of bevacizumab treatment response and outcome in patients with colorectal cancer liver metastases: a multicentre cohort study.

BACKGROUND: Accurate tumour response prediction to targeted therapy allows for personalised conversion therapy for patients with unresectable colorectal cancer liver metastases (CRLM). In this study, …

Thérapies de Conversion

Zhou, S., Sun, D., Mao, W., Liu, Y., Cen, W., Ye, L., Liang, F., Xu, J., Shi, H., Ji, Y., Wang, L., & Chang, W. (2023). Deep radiomics-based fusion model for prediction of bevacizumab treatment response and outcome in patients with colorectal cancer liver metastases: a multicentre cohort study.. EClinicalMedicine, 65, 102271. https://doi.org/10.1016/j.eclinm.2023.102271

01/11/2023 Lire →

Survival benefit and impact of adjuvant therapies following FOLFOX-HAIC-based conversion therapy with unresectable hepatocellular carcinoma: a retrospective cohort study.

BACKGROUND: Recently, the conversion therapies of FOLFOX-HAIC for patients with unresectable hepatocellular carcinoma (uHCC) have dramatically increased the tumor responses and conversion rate; thus, …

Thérapies de Conversion

Pan, Y., Yuan, Z., Wang, J., Ngai, S., Hu, Z., Sun, L., Yang, Z., Hu, D., Chen, M., Zhou, Z., & Zhang, Y. (2023). Survival benefit and impact of adjuvant therapies following FOLFOX-HAIC-based conversion therapy with unresectable hepatocellular carcinoma: a retrospective cohort study.. J Cancer Res Clin Oncol, 149(16), 14761-14774. https://doi.org/10.1007/s00432-023-05243-7

01/11/2023 Lire →

Hepatic arterial infusion chemotherapy versus transarterial chemoembolization, potential conversion therapies for single huge hepatocellular carcinoma: a retrospective comparison study.

BACKGROUND: The treatment efficacy of transarterial chemoembolization (TACE) and hepatic arterial infusion chemotherapy (HAIC) for huge single hepatocellular carcinoma (HCC) has not been fully documen…

Thérapies de Conversion

Deng, M., Cai, H., He, B., Guan, R., Lee, C., & Guo, R. (2023). Hepatic arterial infusion chemotherapy versus transarterial chemoembolization, potential conversion therapies for single huge hepatocellular carcinoma: a retrospective comparison study.. Int J Surg, 109(11), 3303-3311. https://doi.org/10.1097/JS9.0000000000000654

01/11/2023 Lire →

Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.

This retrospective multicenter study analyzed 244 patients with unresectable hepatocellular carcinoma treated with lenvatinib (LEN) and atezolizumab + bevacizumab (Atezo + Bev) to examine the characte…

Thérapies de Conversion

Tomonari, T., Tani, J., Sato, Y., Tanaka, H., Tanaka, T., Taniguchi, T., Kawano, Y., Morishita, A., Okamoto, K., Sogabe, M., Miyamoto, H., Masaki, T., & Takayama, T. (2023). Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.. Cancers (Basel), 15(21). https://doi.org/10.3390/cancers15215221

30/10/2023 Lire →

The efficacy and safety of anti-EGFR target agents in patients with potentially resectable metastatic colorectal cancer: a meta-analysis of randomized controlled trials.

BACKGROUND: Adding anti-epidermal growth factor receptor (anti-EGFR) target agents to conversion therapy may improve the resection rates and survival of patients with potentially resectable metastatic…

Thérapies de Conversion

Wang, Y., Li, X., Huang, T., Wang, D., He, Y., Wei, M., Chen, Y., Zheng, M., Shi, Y., & Zhang, J. (2023). The efficacy and safety of anti-EGFR target agents in patients with potentially resectable metastatic colorectal cancer: a meta-analysis of randomized controlled trials.. World J Surg Oncol, 21(1), 340. https://doi.org/10.1186/s12957-023-03222-3

26/10/2023 Lire →

Conversion therapy for advanced cholangiocarcinoma in the era of molecular targeted therapy and immune therapy.

Thérapies de Conversion

Zhang, Z., & Zhang, W. (2023). Conversion therapy for advanced cholangiocarcinoma in the era of molecular targeted therapy and immune therapy.. Hepatobiliary Surg Nutr, 12(5), 772-775. https://doi.org/10.21037/hbsn-23-352

01/10/2023 Lire →

Dual transformation therapy for giant hepatocellular carcinoma: Two case reports and review of literature.

BACKGROUND: In the translational therapy of giant hepatocellular carcinoma (HCC), hepatic arterial infusion chemotherapy (HAIC) combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors (TK…

Thérapies de Conversion

Gao, Q., Zhu, G. Z., Han, C. Y., Ye, X. P., Huang, H. S., Mo, S. T., & Peng, T. (2023). Dual transformation therapy for giant hepatocellular carcinoma: Two case reports and review of literature.. World J Gastrointest Surg, 15(9), 2089-2097. https://doi.org/10.4240/wjgs.v15.i9.2089

27/09/2023 Lire →

Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.

BACKGROUND: Over 70% of the patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage and lose the opportunity for radical surgery. Combination therapy of tyrosine kinase inhibit…

Thérapies de Conversion

Zhang, W., Tong, S., Hu, B., Wan, T., Tang, H., Zhao, F., Jiao, T., Li, J., Zhang, Z., Cai, J., Ye, H., Wang, Z., Chen, S., Wang, Y., Li, X., Wang, F., Cao, J., Tian, L., Zhao, X., … Lu, S. (2023). Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.. J Immunother Cancer, 11(9). https://doi.org/10.1136/jitc-2023-007366

01/09/2023 Lire →

Radio-granular hydrogels for image-guided tumor brachytherapy.

Thérapies de Conversion

Shao, S., Xu, X., Lin, G., & Liu, G. (2023). Radio-granular hydrogels for image-guided tumor brachytherapy.. ILIVER, 2(3), 177-179. https://doi.org/10.1016/j.iliver.2023.08.006

01/09/2023 Lire →

Evaluating Tislelizumab, Lenvatinib, and FOLFOX4-HAIC as a Conversion Therapy for Unresectable Hepatocellular Carcinoma.

BACKGROUND AND AIMS: Conversion therapy downstages tumors and renders patients with unresectable hepatocellular carcinoma (HCC) eligible for radical resection. This study aimed to evaluate the efficac…

Thérapies de Conversion

Tan, K., He, X., Yuan, H., Zhao, S., Gong, C., Zhao, Y., Nan, H., Zang, L., Luo, Z., & Du, X. (2023). Evaluating Tislelizumab, Lenvatinib, and FOLFOX4-HAIC as a Conversion Therapy for Unresectable Hepatocellular Carcinoma.. ILIVER, 2(3), 163-169. https://doi.org/10.1016/j.iliver.2023.08.003

01/09/2023 Lire →

Preoperative chemotherapy prior to primary tumour resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: The RECUT multicenter randomised controlled trial.

PURPOSE: Primary tumour resection (PTR) is still a selection for patients with low tumour burden and good condition, especially with conversion therapy purpose for colorectal liver-limited metastases …

Thérapies de Conversion

Lin, Q., Ding, K., Zhao, R., Wang, H., Wei, Y., Ren, L., Ye, Q., Cui, Y., He, G., Tang, W., Feng, Q., Zhu, D., Chang, W., Wang, X., Liang, L., Zhou, G., Liang, F., Ye, F., Wang, J., … Xu, J. (2023). Preoperative chemotherapy prior to primary tumour resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: The RECUT multicenter randomised controlled trial.. Eur J Cancer, 191, 112961. https://doi.org/10.1016/j.ejca.2023.112961

01/09/2023 Lire →